A drug from the Japanese Eisai and the American Biogen shows promising results in slowing the cognitive decline associated with Alzheimer’s. However, the consensus is not complete: some see it as a revolutionary advance, while others believe that the impact on the daily life of patients might not be as significant. We explain to them.
#Health #lights #shadows #promise #lecanemab #drug #Alzheimers
Teacher wins award for promoting anti-racist education for babies
Estadão Contenti Estadão Content https://istoedinheiro.com.br/autor/estadao-conteudo/ 09/28/2024 - 17:40 In the city of Lauro de Freitas, in the metropolitan region of...